Filing Overview
Adagio Therapeutics, Inc. (now identified in the request as Invivyd, Inc.) filed a Form 8-K dated March 18, 2022, reporting executive compensation changes and the scheduled 2022 annual meeting of stockholders. The company’s common stock traded under the symbol ADGI on Nasdaq.
Business Context and Reporting Period
This is a current report covering events occurring on March 18, 2022. It does not provide quarterly or annual financial results.
Key Financial Metrics
- Revenue, profit, cash flow, margins, debt, and liquidity: The filing does not provide financial statement data or clear values for these metrics.
- Executive compensation: Jane Pritchett Henderson’s annual base salary was increased to $510,000 following her appointment as Chief Business Officer.
- Target bonus: She remains eligible for an annual target bonus equal to 40% of base salary, or $204,000 based on the stated salary, subject to the employment agreement’s terms.
Material Changes
- Effective March 18, 2022, the Board appointed Ms. Henderson, previously the company’s principal financial officer and Chief Financial Officer, as Chief Business Officer. She will continue serving as Chief Financial Officer.
- The amended employment arrangements provide potential severance upon qualifying termination without cause or for good reason, including nine months of base salary, certain bonus treatment, nine months of benefit continuation, and delayed forfeiture of certain unvested time-based equity awards.
- Additional severance benefits may apply in connection with certain terminations following a change in control.
Outlook, Risks, and Unusual Items
- The filing provides no operating or financial guidance.
- Potential future compensation obligations include salary, target bonus eligibility, severance, benefit continuation, and equity-award treatment under specified termination scenarios.
- The filing does not quantify the potential cost of change-in-control benefits or other contingent compensation obligations.
- The company announced that its 2022 annual meeting of stockholders will be held virtually on May 26, 2022, at 8:30 a.m. Eastern Time.
Important Facts to Verify
- Review the complete amended and restated employment agreement filed as Exhibit 99.1 for the precise severance, change-in-control, equity, and termination provisions.
- Confirm the company’s current legal name, ticker, and executive roles, given the filing identifies the registrant as Adagio Therapeutics, Inc.
- Review subsequent filings for any changes to Ms. Henderson’s position, compensation, or employment status.
- Review the annual meeting materials for proposals, voting matters, and any subsequent corporate actions.